Kenneth Verstraete

Kenneth Verstraete

Auto-generated profile, based on publicly available information

Kenneth Verstraete

Unit for Structural Biology, Department of Biochemistry and Microbiology, Ghent University

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2019 in Science
Verified
Journal Article
Closed access
PDF file
EPEmma K. Persson
Emma K. Persson
KVKenneth Verstraete
Kenneth Verstraete
IHInes Heyndrickx
Ines Heyndrickx
EGElien Gevaert
Elien Gevaert
HAHelena Aegerter
Helena Aegerter
BLBart N. Lambrecht
Bart N. Lambrecht
A crystal-clear ingredient for allergy?: Charcot-Leyden crystals (CLCs) are formed from the eosinophil granule protein galectin-10 (Gal10) and found in severe eosinophil-associated diseases like asthma and chronic rhinosinusitis. Whether CLCs actively contribute to disease pathogenesis is unknown. Persson et al. found that lab-grown Gal10 crystals are biosimilar to CLCs (see the Perspective by Allen and Sutherland). When given to mice, the crystals acted as a type 2 adjuvant, mimicking many of the features of human asthma. In contrast, a Gal10 mutein unable to crystallize had no effect. Antibodies against epitopes crucial for Gal10 autocrystallization could dissolve both in vitro–generated Gal10 crystals and patient-derived CLCs. Furthermore, these anti-Gal10 antibodies reversed the effects of Gal10 crystals in a humanized mouse model of asthma, suggesting a potential therapeutic approach for crystallopathies more broadly. Science , this issue p. eaaw4295 ; see also p. 738

3 April 2019 in Nature
Verified
Journal Article
Closed access
PDF file
KVKoen H. G. Verschueren
Koen H. G. Verschueren
CBClement Blanchet
Clement Blanchet
JFJan Felix
Jan Felix
ADAnn Dansercoer
Ann Dansercoer
DVDirk De Vos
Dirk De Vos
KVKenneth Verstraete
Kenneth Verstraete

3 April 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
KVKenneth Verstraete
Kenneth Verstraete
FPFrank Peelman
Frank Peelman
HBHarald Braun
Harald Braun
JLJuan Lopez
Juan Lopez
DRDries Van Rompaey
Dries Van Rompaey
SSSavvas N. Savvides
Savvas N. Savvides
The pro-inflammatory cytokine thymic stromal lymphopoietin (TSLP) is pivotal to the pathophysiology of widespread allergic diseases mediated by type 2 helper T cell (Th2) responses, including asthma and atopic dermatitis. The emergence of human TSLP as a clinical target against asthma calls for maximally harnessing its therapeutic potential via structural and mechanistic considerations. Here we employ an integrative experimental approach focusing on productive and antagonized TSLP complexes and free cytokine. We reveal how cognate receptor TSLPR allosterically activates TSLP to potentiate the recruitment of the shared interleukin 7 receptor α-chain (IL-7Rα) by leveraging the flexibility, conformational heterogeneity and electrostatics of the cytokine. We further show that the monoclonal antibody Tezepelumab partly exploits these principles to neutralize TSLP activity. Finally, we introduce a fusion protein comprising a tandem of the TSLPR and IL-7Rα extracellular domains, which harnesses the mechanistic intricacies of the TSLP-driven receptor complex to manifest high antagonistic potency.

18 October 2012 in Nature Reviews Cancer
Verified
Journal Article
Closed access
KVKenneth Verstraete
Kenneth Verstraete
SSSavvas N. Savvides
Savvas N. Savvides

7 July 2011 in Blood
Verified
Journal Article
Closed access
KVKenneth Verstraete
Kenneth Verstraete
GVGonzalez Vandriessche
Gonzalez Vandriessche
MJMariska Januar
Mariska Januar
JEJonathan Elegheert
Jonathan Elegheert
ASAlexander V. Shkumatov
Alexander V. Shkumatov
SSSavvas N. Savvides
Savvas N. Savvides
The class III receptor tyrosine kinase (RTKIII) Fms-like tyrosine kinase receptor 3 (Flt3) and its cytokine ligand (FL) play central roles in hematopoiesis and the immune system, by establishing signaling cascades crucial for the development and homeostasis of hematopoietic progenitors and antigen-presenting dendritic cells. However, Flt3 is also one of the most frequently mutated receptors in hematologic malignancies and is currently a major prognostic factor and clinical target for acute myeloid leukemia. Here, we report the structural basis for the Flt3 ligand-receptor complex and unveil an unanticipated extracellular assembly unlike any other RTKIII/V complex characterized to date. FL induces dimerization of Flt3 via a remarkably compact binding epitope localized at the tip of extracellular domain 3 of Flt3, and it invokes a ternary complex devoid of homotypic receptor interactions. Comparisons of Flt3 with homologous receptors and available mutagenesis data for FL have allowed us to rationalize the unique features of the Flt3 extracellular assembly. Furthermore, thermodynamic dissection of complex formation points to a pronounced enthalpically driven binding event coupled to an entropic penalty. Together, our data suggest that the high-affinity Flt3:FL complex is driven in part by a single preformed binding epitope on FL reminiscent of a “lock-and-key” binding mode, thereby setting the stage for antagonist design.

30 October 2014 in Nature Communications
Verified
Journal Article
Open access
JDJohan Desmet
Johan Desmet
KVKenneth Verstraete
Kenneth Verstraete
YBYehudi Bloch
Yehudi Bloch
ELEric Lorent
Eric Lorent
YWYurong Wen
Yurong Wen
SSSavvas N. Savvides
Savvas N. Savvides
Protein scaffolds can provide a promising alternative to antibodies for various biomedical and biotechnological applications, including therapeutics. Here we describe the design and development of the Alphabody, a protein scaffold featuring a single-chain antiparallel triple-helix coiled-coil fold. We report affinity-matured Alphabodies with favourable physicochemical properties that can specifically neutralize human interleukin (IL)-23, a pivotal therapeutic target in autoimmune inflammatory diseases such as psoriasis and multiple sclerosis. The crystal structure of human IL-23 in complex with an affinity-matured Alphabody reveals how the variable interhelical groove of the scaffold uniquely targets a large epitope on the p19 subunit of IL-23 to harness fully the hydrophobic and hydrogen-bonding potential of tryptophan and tyrosine residues contributed by p19 and the Alphabody, respectively. Thus, Alphabodies are suitable for targeting protein–protein interfaces of therapeutic importance and can be tailored to interrogate desired design and binding-mode principles via efficient selection and affinity-maturation strategies.